|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The formation of perovskite multiple quantum well structures for high performance light-emitting diodes显示文摘Recent works showed that high efficient perovskite light-emitting diodes can be achieved from solution-processed,self-organized multiple quantum wells(MQWs)with an energy cascade.We investigate how the mixing of QWs with different band gaps can affect the perovskite LED device performance.We find that the annealing process can significantly affect the constitution of the MQWs films,where the dominant phase can evolve from large band gap QWs to small band gap QWs.The optimal constitution for LED application lies in a transition point of small-n QWs dominant phase to large-n QWs dominant phase,when the MQW film presents highest photoluminescence while still remains uniform film morphology. | Yan Sun Li Zhang Nana Wang Shuting Zhang Yu Cao Yanfeng Miao Mengmeng Xu Hao Zhang Hai Li Chang Yi Jianpu Wang Wei Huang | 2018 | npj Flexible Electronics2018，2，1： | 4 |
| 2 | Medicinal Mushroom Products:Nutriceuticals and/or Pharmaceuticals?显示文摘Although the effectiveness of mushroom products(mushroom derivatives) has been confirmed repeatedly by numerous laboratory experiments and,in some cases,human trials,precisely how these products work is still a matter of conjecture.Studies on the effectiveness of mushroom products fall into two general categories.One approach has been to isolate and determine the bioactivity of individual mushroom components within a particular class of compounds(e.g.polysaccharides,lectins,triterpenoids,fungal immunomodulatory proteins).The active principal component is then sold in refined or purified form,e.g.the polysaccharide lentinan from the edible/medicinal mushroom Lentinula edodes.Such an approach is certainly valid if the objective is to focus on a single mushroom-derived substance for the treatment of specific disease conditions,e.g.cancers or strokes.In such cases,the products might be(and have been) developed and marketed as prescription drugs.However,an alternative approach is not to focus on a single component within a class of compounds but on groups of compounds that improve overall health and the general quality of life.These composite formulae,in which several different compounds together contribute to the beneficial effect of the mushroom,could then be used collectively as a dietary supplement(nutriceutical).Thus,the medicinal effects afforded by medicinal mushroom products may be attributable to several quite different types of compounds present in the mushrooms,e.g.polysaccharides,lectins,triterpenoids and fungal immunomodulatory proteins.These compounds,and possibly others yet to be identified,appear to act in concert in contributing to the documented anticancer,antitumour,antiviral,antibacterial and immunomodulating properties of the mushroom.Therefore,mushroom nutriceuticals may be deemed to have multifunctional values,the essence of which depends on the integrated effects of the various compounds.Certainly,the overwhelming majority of mushroom-based products currently available are not single components but combinations of several groups of compounds('crude extracts') that together contribute to the overall medicinal effect of the product.Therefore,it is important that future development of mushroom nutriceuticals places emphasis on investigating the functionality and interaction of the groups of compounds found in mushrooms.In some cases,it may be more desirable to consider the total medicinal effect(s) of mushroom 'crude extracts'(comprising groups of compounds) and then to ascertain the contributions made to the overall activity by individual components.The consistency of the 'crude extracts',both in terms of the overall chemical composition and in the actual levels of active components,between different batches could be standardized on the basis of one or two of the main components.This is essential for ensuring some degree of uniformity in prescribed dosages.Thus,while the minimum dosage of an active component required to bring about the desired therapeutic effect is often known for similar products,e.g.hypericin in extracts of St.John's Wort,this is generally not the case where mushroom 'crude extracts' are concerned.This is an area where scientific validation can increase knowledge of the products themselves as well as contributing to product quality control. | CHANG Shuting | 2009 | 食用菌学报2009，16，4： | 2 |
| 3 | Mushrooms as human food显示文摘 | | 1980 | Bioscience1980，30，6： | 1 |
| 4 | A Study ofMicropool Lubricated Cutting Tool in Machining of Mild Steel 显示文摘 | Shuting Ii Sasikumar Devarajan Zenghu Chang | 2009 | Journal of Materials Processing Technology2009，209，： | 1 |
| 5 | A study of micropool lubricated cutting tool in machining of mild steel显示文摘 | Shuting Lei Sasikumar Devarajan Zenghu Chang | 2008 | Journal of Materials Processing Tech2008，，3： | 1 |
| 6 | Global impact of edible and medicinal mushrooms on human welfare in the 21st century:nongreen revolution显示文摘 | | 1999 | International Journal of Medicinal Mushroom1999，1，1： | 1 |
| 7 | A study of micropool lubricated cutting tool in machining of mild steel 显示文摘 | Shuting Lei Sasikumar Devarajan Zenghu Chang | 2009 | Journal of Materials Processing Technology2009，209，： | 1 |
| 8 | A study of micropool lubricated cutting tool in ma- chining of mild steel显示文摘 | Shuting Lei Sasikumar Devarajan Zenghu Chang | 2009 | Joumal of Materials Pro- cessing Technology2009，，209： | 1 |
| 9 | A study of mieropool lubricated curing tool in machining of mild steel显示文摘 | Lei Shuting Devarajan S Chang Zenghu | 2009 | Journal of Materials Processing Technology2009，209，： | 1 |
| 10 | Prevalence of Congenital Heart Disease at Extremely High Altitudes in Tibet and the Establishment of a New Free Treatment Model显示文摘Background: This study aimed to illustrate the prevalence of CHD by screening children in extremely high-altitudeareas (over 4000 m to even 5000 m above sea level) and explore an aid model for early diagnosis and treatmentfor the Tibetan population. Methods: A total of 2242 students from different schools in Ngamring County,Xigaze City, Tibet from September 2019 to September 2020 were selected for screening. The students were examinedthrough the inquiry of their current medical history and family history, cardiac auscultation and a physicalexamination, in order to screen out the suspected cases of CHD, and then the suspected cases were confirmed bycardiac color ultrasound examinations. After that, positive patients were be transferred to Shandong Province forfree treatment. Results: The prevalence of CHD among children in Ngamring County was 3.70% (83 cases),which is the highest incidence rate ever reported. The most common type of CHD was patent ductus arteriosus(PDA), accounting for 55.42% of the total number of cases screened, followed by atrial septal defect (ASD) andventricular septal defect (VSD), accounting for 28.92% and 12.05%, respectively. The prevalence of CHD in childrenat high altitude was significantly higher than that in children at low altitude. The children with CHD weretransferred to Shandong Province for surgery, the operations were successful and their recoveries went well.Conclusions: The results show that high altitude is closely related to the prevalence of CHD, and the incidencein Ngamring County is much higher than that in previous reports. | Shuting Chang Guanzhao Zhang Nengjun Sun Xinpeng Yuan Qingting Wang Lin Zhu Feiyue Zhang Yu Xiu Yang Dong Yonghong Chen Zhanpeng Zhao Xiao Liu Qiang Shao Xiaofeng Xu Anshun Wang Mengjiao Li Bo Li | 2022 | Congenital Heart Disease2022，17，6： | 1 |
| 11 | A study of micropool lubricated cutting tool in machining of mild steel显示文摘 | Lei Shuting Devarajan S Chang Zenghu | 2009 | Journal of Materials Processing Technology2009，209，2009： | 1 |
| 12 | A study of micropool lubricated cutting tool in machining of mild steel 显示文摘 | Shuting Lei Sasikumar Devarajan Zenghu Chang | 2009 | Journal of Materials Processing Technology2009，209，3： | 1 |
| 13 | A study of micro-pool lubricated cutting tool in machining of mild steel 显示文摘 | Lei Shuting Devarajan S Chang Zenghu | 2009 | Journal of Materials Processing Technology2009，209，3： | 1 |
| 14 | Alternative Splicing of OsRAD1 Defines C-Terminal Domain Essential for Protein Function in Meiosis显示文摘Alternative splicing can generate multiple mRNAs that differ in their untranslated regions or coding sequences,and these differences might affect mRNA stability or result in different protein isoforms with diverse functions and/or localizations.In this study,we isolated a sterile mutant in rice with abnormal meiosis of microspore mother cells and megaspore mother cells that carried a point mutation in OsRAD1 gene.Cloning of OsRAD1 cDNAs revealed three transcript variants,named as OsRAD1.1,OsRAD1.2 and OsRAD1.3,respectively,which were derived from alternative splicing of the last intron.Proteins derived from the three transcripts were mostly identical except the difference in the very C-terminal domain.The three transcripts exhibited similar expression patterns in various tissues,but the expression level of OsRAD1.1 was the highest.Specific knockout of OsRAD1.1 led to sterility,while knockout of OsRAD1.2 and OsRAD1.3 together did not change the plant fertility.Overexpression of OsRAD1.2 and OsRAD1.3 cDNAs in OsRAD1.1-specific mutant did not complement the plant fertility.Yeast two-hybrid assay showed that OsRAD1.1,but not OsRAD1.2 and OsRAD1.3,interacted with the three other meiosis proteins OsHUS1,OsRAD9 and OsRAD17,suggesting that the C-terminal domain of OsRAD1.1 is critical for the protein function. | YUAN Shuting XU Chunjue YAN Wei CHANG Zhenyi DENG Xingwang CHEN Zhufeng WU Jianxin TANG Xiaoyan | 2020 | Rice science2020，27，4： | 0 |
| 15 | The benefits of PCSK9 inhibitors in patients with acute coronary syndrome:a systematic review and meta-analysis显示文摘Background:Proprotein convertase subtilisin/kexin 9(PSCK9)inhibitors have been beneficial for many patients with hyperlipidemia.The objective of this study was to investigate the benefit of PSCK9 inhibitors in patients with acute coronary syndrome(ACS).Methods:We systematically searched PubMed,EMBASE,and Cochrane Clinical Trials(published before January 2023;no language restriction)to compare the treatment of patients with ACS using PCSK9 inhibitors and placebo.The primary end points were major adverse cardiovascular events,nonfatal myocardial infarction,cardiogenic death,stroke,hospitalization for recurrent ACS,and coronary revascularization.Fixed-or random-effects models were used to assess the aggregated data.Results:Of the 1686 identified studies,5 were eligible and included in our analysis(of a total of 38,005 participants,18,609 cases were placed in the PCSK9 inhibitor treatment group and 19,396 cases in the placebo group).Compared with the placebo group,PCSK9 inhibitors significantly reduced the major adverse cardiovascular events(odds ratio[OR]:0.83;95%confidence interval[CI]:0.77–0.88;P<0.00001)for patients following ACS.The incidence of nonfatal myocardial infarction(relative risk:0.80;95%CI:0.74–0.87;P<0.00001),cardiovascular death(OR:0.96;95%CI:0.83–1.10;P=0.56),stroke(OR:0.74;95%CI:0.63–0.88;P=0.0007),hospitalization for recurrent ACS(OR:0.57;95%CI:0.40–0.83;P=0.003),or coronary revascularization(OR:0.82;95%CI:0.76–0.88;P<0.00001)all demonstrated a significant decrease in the comparison between the 2 groups.Conclusion:This meta-analysis demonstrated that treatment with PCSK9 inhibitors in patients with ACS reduced the probability of multiple cardiovascular events and improved patient prognosis. | Guanzhao Zhang Shuting Chang Faming Zhao Xiangfeng Guan Zifan Nie Wenhao Liu Bo Li | 2024 | Emergency and Critical Care Medicine2024，4，1： | 0 |
| 16 | Drug-coated balloons are not inferior to drug-coated stents in the treatment of acute myocardial infarction and shorten the duration of dual antiplatelet treatment显示文摘Background:Drug-coated balloons(DCBs)are an up-and-coming tactic in treating in-stent restenosis and coronary artery small vessel disease,but their efficacy in treating acute myocardial infarction needs to be further explored.Methods:A meta-analysis of 7 studies was conducted to make a comparison with the results of DCB and drug-eluting stent implantation after a median follow-up of 15 months.Results:A total of 922 patients were included in this analysis in total,including 375 patients in the DCB group and 547 patients in the stent group.A total of 962 vascular diseases were manifested in the 2 groups.After 6 to 24 months of follow-up,there was no statistically significant difference with respect to major adverse cardiovascular events(odds ratio[OR]:0.82;95%confidence interval[CI]:0.52–1.29;Z=0.85;P=0.39),cardiac death(OR:0.92;95%CI:0.39–2.12;Z=0.21;P=0.84),target lesion revascularization(OR:1.09;95%CI:0.53–2.25;Z=0.24;P=0.81),late lumen loss(MD:−0.05;95%CI:−0.15 to 0.06;Z=0.85;P=0.40),or dual antiplatelet therapy(DAPT)(OR:1.04;95%CI:0.53–2.05;Z=0.11;P=0.91)between the 2 groups.In the DCB group,persistent residual stenosis or C-F dissection occurrence necessitated that a total of 30 patients receive extra bailout implantations.The rate of bailout stenting was 11.8%(95%CI:7.1–16).Moreover,the DCB group had a shorter DAPT duration compared with the stent group.Conclusion:Drug-coated balloons with shorter DAPT durations may be as effective and safe as stent therapy in treating acute myocardial infarction. | Jing Yang Shuting Chang Jing Liu Guanzhao Zhang Yue Wang Baixue Zhang Zifan Nie Yuanbao Dong Bo Li | 2022 | Emergency and Critical Care Medicine2022，2，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员